Cannabis Science Inc (OTCMKTS:CBIS)
Cannabis Science Inc (OTCMKTS:CBIS) has announced the release of its first cannabinoid-based suppositories for both male and female patients. The suppositories help alleviate symptoms related to anxiety, cancer, pain relief, and insomnia. The Unisex Suppository Regimen Package is the first of the three regimen packages which Cannabis Science will be releasing to aid in addressing the high demand for cannabinoid-based treatments for patients seeking alternative medical treatments.
The suppositories are 50% – 70% more effective and produce more predictable results compared to ingested or smoked cannabis. Suppositories are also more effective in the treatment of pelvic and lower gastrointestinal conditions. They are effective in treating people suffering from nausea and vomiting, or with people who have problems swallowing pills.
While commenting on their newest product offering, Cannabis Science Inc (OTCMKTS:CBIS)’s Chief Medical Officer, Dr. Allen Herman, said the release is a milestone in the company’s move to offer innovative and diversified solutions to patients in need of relief that can be provided by cannabinoids. He added that the company expects the new suppository regimens to increase demand for cannabinoid-based medicines. Through the launch of the unisex regimens for the self-medicating patients, the company is hoping to track and monitor the use of cannabinoid-based medicines using dispensaries as well as observing the effectiveness of this formulation and delivery system. The process, which will be part of the overall follow-up, observation, and testing protocol, will enable Cannabis Science Inc (OTCMKTS:CBIS) to come up with more products that can help meet consumer demand. The company is currently admitting patients who wish to take part in the observational study.
Mr. Raymond C. Dabney, the President & CEO and Co-founder of Cannabis Science Inc (OTCMKTS:CBIS) said the release of Cannabis Science’s Unisex Suppository Regimen is an important step taken by the company in building it cannabinoid-based medicines portfolio. He added that although the regimen is designed for both men and women, the company intends to come up with gender-specific options.
Cannabis Science Inc (OTCMKTS:CBIS) is currently trading around $0.06, well down from its $0.13 high in February. One positive characteristic about CBIS share is that they are among the most liquid on the OTCPink exchange.
I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.
About the author: Jack is originally from Scotland and arrived in the USA 20 years ago to study chemistry. His studies led him to a job with a Fortune 500 company and then to a stint as an analyst for a private equity firm. After the 2008 stock market meltdown Jack returned to Scotland where he works full-time as an analyst and travel writer.